stockportfolio.pro
Stocks / NVAX vs STAA
NVAX vs STAA
Novavax, Inc. and STAAR Surgical Company side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Novavax, Inc. (NVAX) | STAAR Surgical Company (STAA) | |
|---|---|---|
| Market cap | $1.4B | $1.5B |
| Revenue (latest FY) | $1.12B | $239.44M |
| Net income (latest FY) | $440.30M | $-80.45M |
| Revenue growth (5y CAGR) | 18.8% | 7.9% |
| Net margin | 39.2% | -33.6% |
| Return on equity | -344.7% | -23.4% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 6 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open NVAX — free Open STAA — freeFrequently asked questions
Which is bigger, NVAX or STAA?
STAAR Surgical Company is larger by market capitalization — $1.5B versus $1.4B.
Which grows faster, NVAX or STAA?
Over the last five fiscal years, Novavax, Inc. grew revenue faster — 18.8%/yr versus 7.9%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.